多重向的基于胰岛素的纳米颗粒与大麻二醇用于有效预防性结肠炎
Xuan Zhang1,2,3, Xia Gao1,2,3, Xiangzhou Yi1,2,3
1College of Food Science and Engineering, Hainan University, Haikou, 570228, China.
Materials today. Bio
|February 6, 2024
概括
含有大麻 (CBD) 的线粒体/结肠双纳米颗粒通过减少炎症和恢复肠道屏障功能,有效治疗性结肠炎 (UC). 这些氧化还原响应纳米颗粒改善了肠道微生物群平衡,以加强UC治疗.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 胃肠病学 胃肠病学
背景情况:
- 性结肠炎 (UC) 的发病包括炎症,屏障损伤,氧化应激和肠道失调.
- 目前的UC治疗面临着由于药物分布和生物可用性差的挑战.
- 需要有针对性的输送系统来克服UC治疗中的这些局限性.
研究的目的:
- 开发新的线粒体/结肠双重向纳米颗粒,用于增强大麻 (CBD) 输送.
- 在性结肠炎的临床前模型中研究这些纳米颗粒的治疗疗效.
- 评估纳米粒子恢复肠道屏障功能和调节肠道微生物群的能力.
主要方法:
- 使用TPP-IN-LA聚合物通过自组装合成了大麻纳米颗粒 (CBDNP).
- 使用光显微镜和*in vivo*成像,评估了线粒体向和结肠积累.
- 谷氨刺激的药物释放被测量在生理pH值.
- *体内*研究涉及小鼠的DSS诱导性结肠炎模型,以评估治疗效果.
主要成果:
- CBD NPs表现出有效的线粒体向 (皮尔森系数0.76) 和结肠积累.
- 在pH值7.4时观察到由谷氨触发的CBD显著释放.
- CBD NPs改善了DSS诱导的大肠炎,调节了TLR4-NF-κB通路,并改善了组织学损伤.
- 观察到紧结蛋白ZO-1表达的恢复,改善屏障功能和肠道微生物群的正常化.
结论:
- 线粒体/结肠双重向,氧化还原反应CBDNP为UC治疗提供了一个有前途的策略.
- 这些纳米颗粒有效地将CBD传递到目标部位,减少炎症并恢复肠道完整性.
- 这种方法有可能通过解决关键的病理特征来改善性结肠炎的治疗结果.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141
Drugs for Treatment of Diarrhea-Predominant IBS
175
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
175
Drugs for Treatment of Constipation-Predominant IBS
169
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
169
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
202
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
202


